[Editorial] Drugging the undruggable in pancreatic cancer | ClinicLens

A new drug for pancreatic cancer set ASCO abuzz this May, uniting the plenary hall in standing ovation—in a phase 3 trial, the RAS inhibitor daraxonrasib nearly doubled overall survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Pancreatic cancer is a l

Medical Literature · Updated 2026-08-03

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.